Investment Analysts’ Recent Ratings Updates for Sarepta Therapeutics (SRPT)

Sarepta Therapeutics (NASDAQ: SRPT) has recently received a number of price target changes and ratings updates:

• 7/1/2024 – Sarepta Therapeutics had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $205.00 price target on the stock.
• 6/27/2024 – Sarepta Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $235.00 price target on the stock.
• 6/26/2024 – Sarepta Therapeutics was downgraded by analysts at Citigroup Inc. from a “buy” rating to a “neutral” rating. They now have a $176.00 price target on the stock, up previously from $172.00.
• 6/24/2024 – Sarepta Therapeutics had its price target raised by analysts at SVB Leerink LLC from $165.00 to $230.00. They now have an “outperform” rating on the stock.
• 6/24/2024 – Sarepta Therapeutics had its price target raised by analysts at BMO Capital Markets from $170.00 to $200.00. They now have an “outperform” rating on the stock.
• 6/24/2024 – Sarepta Therapeutics had its price target raised by analysts at Evercore ISI from $139.00 to $185.00. They now have an “in-line” rating on the stock.
• 6/21/2024 – Sarepta Therapeutics had its price target raised by analysts at Royal Bank of Canada from $142.00 to $182.00. They now have a “sector perform” rating on the stock.
• 6/21/2024 – Sarepta Therapeutics had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $157.00 price target on the stock.
• 6/21/2024 – Sarepta Therapeutics had its “overweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $165.00 price target on the stock.
• 6/21/2024 – Sarepta Therapeutics had its price target raised by analysts at Barclays PLC from $185.00 to $226.00. They now have an “overweight” rating on the stock.
• 6/21/2024 – Sarepta Therapeutics had its price target raised by analysts at Robert W. Baird from $170.00 to $200.00. They now have an “outperform” rating on the stock.
• 6/21/2024 – Sarepta Therapeutics had its “neutral” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $128.00 price target on the stock.
• 6/21/2024 – Sarepta Therapeutics had its price target raised by analysts at Needham & Company LLC from $166.00 to $235.00. They now have a “buy” rating on the stock.
• 6/21/2024 – Sarepta Therapeutics had its price target raised by analysts at Bank of America Co. from $166.00 to $213.00. They now have a “buy” rating on the stock.
• 6/14/2024 – Sarepta Therapeutics had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $170.00 price target on the stock.
• 5/31/2024 – Sarepta Therapeutics is now covered by analysts at Piper Sandler. They set an “overweight” rating and a $157.00 price target on the stock.
• 5/28/2024 – Sarepta Therapeutics had its “sector perform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $142.00 price target on the stock, down previously from $157.00.
• 5/20/2024 – Sarepta Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $166.00 price target on the stock.
• 5/17/2024 – Sarepta Therapeutics had its price target raised by analysts at Mizuho from $145.00 to $179.00. They now have a “buy” rating on the stock.
• 5/14/2024 – Sarepta Therapeutics was upgraded by analysts at Oppenheimer Holdings Inc. from a “market perform” rating to an “outperform” rating. They now have a $180.00 price target on the stock.

Sarepta Therapeutics Trading Down 0.7 %

NASDAQ:SRPT opened at $153.11 on Thursday. The stock has a market cap of $14.47 billion, a price-to-earnings ratio of 1,391.91 and a beta of 0.89. The company has a debt-to-equity ratio of 1.18, a quick ratio of 3.44 and a current ratio of 4.05. Sarepta Therapeutics, Inc. has a 1 year low of $55.25 and a 1 year high of $173.25. The business has a fifty day moving average of $131.86 and a 200-day moving average of $123.74.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 EPS for the quarter, beating the consensus estimate of ($0.11) by $0.84. The firm had revenue of $413.50 million for the quarter, compared to analysts’ expectations of $375.52 million. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. Sarepta Therapeutics’s quarterly revenue was up 63.1% on a year-over-year basis. During the same quarter last year, the company earned ($1.44) EPS. Equities analysts predict that Sarepta Therapeutics, Inc. will post 3.71 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Dallan Murray sold 3,635 shares of the firm’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total transaction of $508,900.00. Following the completion of the transaction, the insider now owns 18,125 shares of the company’s stock, valued at $2,537,500. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, insider Dallan Murray sold 3,635 shares of the business’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $140.00, for a total value of $508,900.00. Following the sale, the insider now directly owns 18,125 shares in the company, valued at approximately $2,537,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Ryan Edward Brown sold 38,957 shares of the firm’s stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total transaction of $6,295,840.77. Following the sale, the executive vice president now owns 17,129 shares of the company’s stock, valued at $2,768,217.69. The disclosure for this sale can be found here. Insiders have sold a total of 50,451 shares of company stock valued at $8,086,386 over the last quarter. Corporate insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Principal Securities Inc. acquired a new position in Sarepta Therapeutics in the 4th quarter worth approximately $26,000. Mather Group LLC. purchased a new position in shares of Sarepta Therapeutics during the first quarter valued at $28,000. Riggs Asset Managment Co. Inc. raised its position in Sarepta Therapeutics by 125.0% during the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 125 shares during the period. New Covenant Trust Company N.A. purchased a new stake in Sarepta Therapeutics in the 1st quarter worth about $32,000. Finally, GAMMA Investing LLC boosted its position in Sarepta Therapeutics by 37.0% during the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 87 shares during the period. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.